Drug Search Results
More Filters [+]

Sozinibercept

Alternative Names: Sozinibercept, opt-302, opt302, opt 302
Latest Update: 2024-09-23
Latest Update Note: News Article

Product Description

We are developing a novel therapeutic called OPT-302, a VEGF-C/D trap, to be used in combination with existing standard of care anti-VEGF-A therapies.

Mechanisms of Action: VEGF Inhibitor

Novel Mechanism: No

Modality: Fusion Protein

Route of Administration: Injection

FDA Designation: Fast Track - Macular Degeneration|Wet Macular Degeneration *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Opthea
Company Location: SOUTH YARRA, VICTORIA C3 3141
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sozinibercept

Countries in Clinic: Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, India, Israel, Italy, Korea, Latvia, Lithuania, Malaysia, Netherlands, Philippines, Poland, Puerto Rico, Slovakia, Spain, Taiwan, Thailand, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Neovascular age-related macular degeneration|Wet Macular Degeneration

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

OPT-302-1004

P3

Not yet recruiting

Neovascular age-related macular degeneration|Wet Macular Degeneration

2026-05-31

OPT-302-1005

P3

Not yet recruiting

Wet Macular Degeneration|Neovascular age-related macular degeneration

2026-01-20

COAST

P3

Active, not recruiting

Wet Macular Degeneration|Neovascular age-related macular degeneration

2025-07-01

42%

ShORe

P3

Active, not recruiting

Wet Macular Degeneration|Neovascular age-related macular degeneration

2025-07-01

Recent News Events